Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy

Michael T. Milano, Everett E. Vokes, Joseph K. Salama, Kerstin M. Stenson, Johnny Kao, Mary Ellyn Witt, Bharat B. Mittal, Athanassios Argiris, Ralph R. Weichselbaum, Daniel J. Haraf

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Purpose: We previously demonstrated the efficacy of concurrent gemcitabine, paclitaxel, and 5-fluorouracil in conjunction with twice-daily (1.5-Gy) radiotherapy delivered on alternating weeks (TFGX2) in locally advanced head-and-neck cancer. Here, we report the clinical outcome and late toxicity of TFGX2 in a subset of patients previously irradiated to the head and neck. Methods and Materials: Twenty-nine previously irradiated patients, presenting with recurrent or second primary head-and-neck cancer, underwent TFGX2. Twelve patients underwent attempted surgical resection before chemoradiotherapy, 10 of whom were left with no measurable disease. Patients with measurable disease received a median radiation dose of 72 Gy; those with no measurable disease received a median dose of 61 Gy. The cumulative dose ranged from 74.4 to 156.4 Gy (mean, 125.7 Gy; median, 131.0 Gy). Results: The median follow-up was 19.1 months (50.9 months for living patients). The 5-year overall survival rate was 34.5%, and the locoregional control rate was 54.5%. In patients with measurable disease at treatment, the 5-year overall survival and locoregional control rate was 26.3% and 45.1%, respectively, compared with 50.0% (p = 0.14) and 70% (p = 0.31), respectively, for those with no measurable disease. Measurable disease and radiation dose were highly statistically significant for overall survival and locoregional control on multivariate analysis. Of 14 patients assessable for late toxicity, 3 developed Grade 4-5, 8 Grade 2-3, and 3 Grade 0-1 toxicity. Conclusion: Aggressive reirradiation with chemotherapy in locally advanced head-and-neck cancer provides a chance for long-term cure at the expense of toxicity. Attempted surgical resection before chemoradiotherapy improved disease control and survival.

Original languageEnglish (US)
Pages (from-to)1096-1106
Number of pages11
JournalInternational Journal of Radiation Oncology Biology Physics
Volume61
Issue number4
DOIs
StatePublished - Mar 15 2005
Externally publishedYes

Fingerprint

gemcitabine
chemotherapy
Head and Neck Neoplasms
Paclitaxel
Fluorouracil
cancer
Drug Therapy
toxicity
grade
dosage
Chemoradiotherapy
Survival
Radiation
radiation
Re-Irradiation
set theory
radiation therapy
Neck
Radiotherapy
Multivariate Analysis

Keywords

  • Chemotherapy
  • Fluorouracil
  • Gemcitabine
  • Head-and-neck cancer
  • Paclitaxel
  • Reirradiation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. / Milano, Michael T.; Vokes, Everett E.; Salama, Joseph K.; Stenson, Kerstin M.; Kao, Johnny; Witt, Mary Ellyn; Mittal, Bharat B.; Argiris, Athanassios; Weichselbaum, Ralph R.; Haraf, Daniel J.

In: International Journal of Radiation Oncology Biology Physics, Vol. 61, No. 4, 15.03.2005, p. 1096-1106.

Research output: Contribution to journalArticle

Milano, Michael T. ; Vokes, Everett E. ; Salama, Joseph K. ; Stenson, Kerstin M. ; Kao, Johnny ; Witt, Mary Ellyn ; Mittal, Bharat B. ; Argiris, Athanassios ; Weichselbaum, Ralph R. ; Haraf, Daniel J. / Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. In: International Journal of Radiation Oncology Biology Physics. 2005 ; Vol. 61, No. 4. pp. 1096-1106.
@article{91d3a53d3f0d4953aaed2a98f7384efc,
title = "Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy",
abstract = "Purpose: We previously demonstrated the efficacy of concurrent gemcitabine, paclitaxel, and 5-fluorouracil in conjunction with twice-daily (1.5-Gy) radiotherapy delivered on alternating weeks (TFGX2) in locally advanced head-and-neck cancer. Here, we report the clinical outcome and late toxicity of TFGX2 in a subset of patients previously irradiated to the head and neck. Methods and Materials: Twenty-nine previously irradiated patients, presenting with recurrent or second primary head-and-neck cancer, underwent TFGX2. Twelve patients underwent attempted surgical resection before chemoradiotherapy, 10 of whom were left with no measurable disease. Patients with measurable disease received a median radiation dose of 72 Gy; those with no measurable disease received a median dose of 61 Gy. The cumulative dose ranged from 74.4 to 156.4 Gy (mean, 125.7 Gy; median, 131.0 Gy). Results: The median follow-up was 19.1 months (50.9 months for living patients). The 5-year overall survival rate was 34.5{\%}, and the locoregional control rate was 54.5{\%}. In patients with measurable disease at treatment, the 5-year overall survival and locoregional control rate was 26.3{\%} and 45.1{\%}, respectively, compared with 50.0{\%} (p = 0.14) and 70{\%} (p = 0.31), respectively, for those with no measurable disease. Measurable disease and radiation dose were highly statistically significant for overall survival and locoregional control on multivariate analysis. Of 14 patients assessable for late toxicity, 3 developed Grade 4-5, 8 Grade 2-3, and 3 Grade 0-1 toxicity. Conclusion: Aggressive reirradiation with chemotherapy in locally advanced head-and-neck cancer provides a chance for long-term cure at the expense of toxicity. Attempted surgical resection before chemoradiotherapy improved disease control and survival.",
keywords = "Chemotherapy, Fluorouracil, Gemcitabine, Head-and-neck cancer, Paclitaxel, Reirradiation",
author = "Milano, {Michael T.} and Vokes, {Everett E.} and Salama, {Joseph K.} and Stenson, {Kerstin M.} and Johnny Kao and Witt, {Mary Ellyn} and Mittal, {Bharat B.} and Athanassios Argiris and Weichselbaum, {Ralph R.} and Haraf, {Daniel J.}",
year = "2005",
month = "3",
day = "15",
doi = "10.1016/j.ijrobp.2004.08.029",
language = "English (US)",
volume = "61",
pages = "1096--1106",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy

AU - Milano, Michael T.

AU - Vokes, Everett E.

AU - Salama, Joseph K.

AU - Stenson, Kerstin M.

AU - Kao, Johnny

AU - Witt, Mary Ellyn

AU - Mittal, Bharat B.

AU - Argiris, Athanassios

AU - Weichselbaum, Ralph R.

AU - Haraf, Daniel J.

PY - 2005/3/15

Y1 - 2005/3/15

N2 - Purpose: We previously demonstrated the efficacy of concurrent gemcitabine, paclitaxel, and 5-fluorouracil in conjunction with twice-daily (1.5-Gy) radiotherapy delivered on alternating weeks (TFGX2) in locally advanced head-and-neck cancer. Here, we report the clinical outcome and late toxicity of TFGX2 in a subset of patients previously irradiated to the head and neck. Methods and Materials: Twenty-nine previously irradiated patients, presenting with recurrent or second primary head-and-neck cancer, underwent TFGX2. Twelve patients underwent attempted surgical resection before chemoradiotherapy, 10 of whom were left with no measurable disease. Patients with measurable disease received a median radiation dose of 72 Gy; those with no measurable disease received a median dose of 61 Gy. The cumulative dose ranged from 74.4 to 156.4 Gy (mean, 125.7 Gy; median, 131.0 Gy). Results: The median follow-up was 19.1 months (50.9 months for living patients). The 5-year overall survival rate was 34.5%, and the locoregional control rate was 54.5%. In patients with measurable disease at treatment, the 5-year overall survival and locoregional control rate was 26.3% and 45.1%, respectively, compared with 50.0% (p = 0.14) and 70% (p = 0.31), respectively, for those with no measurable disease. Measurable disease and radiation dose were highly statistically significant for overall survival and locoregional control on multivariate analysis. Of 14 patients assessable for late toxicity, 3 developed Grade 4-5, 8 Grade 2-3, and 3 Grade 0-1 toxicity. Conclusion: Aggressive reirradiation with chemotherapy in locally advanced head-and-neck cancer provides a chance for long-term cure at the expense of toxicity. Attempted surgical resection before chemoradiotherapy improved disease control and survival.

AB - Purpose: We previously demonstrated the efficacy of concurrent gemcitabine, paclitaxel, and 5-fluorouracil in conjunction with twice-daily (1.5-Gy) radiotherapy delivered on alternating weeks (TFGX2) in locally advanced head-and-neck cancer. Here, we report the clinical outcome and late toxicity of TFGX2 in a subset of patients previously irradiated to the head and neck. Methods and Materials: Twenty-nine previously irradiated patients, presenting with recurrent or second primary head-and-neck cancer, underwent TFGX2. Twelve patients underwent attempted surgical resection before chemoradiotherapy, 10 of whom were left with no measurable disease. Patients with measurable disease received a median radiation dose of 72 Gy; those with no measurable disease received a median dose of 61 Gy. The cumulative dose ranged from 74.4 to 156.4 Gy (mean, 125.7 Gy; median, 131.0 Gy). Results: The median follow-up was 19.1 months (50.9 months for living patients). The 5-year overall survival rate was 34.5%, and the locoregional control rate was 54.5%. In patients with measurable disease at treatment, the 5-year overall survival and locoregional control rate was 26.3% and 45.1%, respectively, compared with 50.0% (p = 0.14) and 70% (p = 0.31), respectively, for those with no measurable disease. Measurable disease and radiation dose were highly statistically significant for overall survival and locoregional control on multivariate analysis. Of 14 patients assessable for late toxicity, 3 developed Grade 4-5, 8 Grade 2-3, and 3 Grade 0-1 toxicity. Conclusion: Aggressive reirradiation with chemotherapy in locally advanced head-and-neck cancer provides a chance for long-term cure at the expense of toxicity. Attempted surgical resection before chemoradiotherapy improved disease control and survival.

KW - Chemotherapy

KW - Fluorouracil

KW - Gemcitabine

KW - Head-and-neck cancer

KW - Paclitaxel

KW - Reirradiation

UR - http://www.scopus.com/inward/record.url?scp=20044383937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044383937&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2004.08.029

DO - 10.1016/j.ijrobp.2004.08.029

M3 - Article

C2 - 15752889

AN - SCOPUS:20044383937

VL - 61

SP - 1096

EP - 1106

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -